About this item:

161 Views | 88 Downloads

Author Notes:

Correspondence: Donald L. Bliwise, Ph.D., Sleep Program, Emory University School of Medicine, 12 Executive Park Drive, Room 435, Atlanta, Georgia 30329, Phone 404-712-7241, FAX 404-712-8145, dbliwis@emory.edu

Donald L. Bliwise conceived of the project, analyzed the data and drafted the manuscript.

Sophia A. Greer and Michael K. Scullin provided biostatistical support.

Lawrence S. Phillips obtained funding for the work, provided oversight of data collection and drafted portions of the manuscript.

Donald L. Bliwise Sophia A. Greer, Michael K. Scullin, and Lawrence S. Phillips all edited the manuscript for critical content.

All authors approved the final version of the manuscript.

Donald L. Bliwise is the guarantor of this work and, as such, takes responsibility for the integrity of the information provided.

The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

This work is not intended to reflect the official opinion of the VA or the U.S. government.

The authors declare that there is no conflict of interest associated with this manuscript.

With regard to potential conflicts of interest, within the past several years, DLB has served as Consultant to New England Research Institute; Ferring Pharmaceuticals; Morehouse School of Medicine; Vantia Therapeutics; Georgia Institute of Technology and Merck.

These activities are unrelated to the current work.

SAG and MKS have nothing to report.

LSP served on Scientific Advisory Boards for Boehringer Ingelheim and Janssen, and has or had research support from Merck, Amylin, Eli Lilly, Novo Nordisk, Sanofi, PhaseBio, Roche, the Cystic Fibrosis Foundation, Glaxo SmithKline, and Vascular Pharmaceuticals.

The above activities involve diabetes, but have nothing to do with this manuscript.

Subjects:

Research Funding:

This work was supported in part by NIH awards DK066204 (LSP), DK099716 (LSP), NS050595 (DLB), AG041543 (MKS), and UL1 RR025008 (LSP), VA award HSR&D IIR 07-138 (LSP), Cystic Fibrosis Foundation award PHILLI12A0 (LSP), Emory Neuroscience Initiative Award (DLB); and the United States Department of Veterans Affairs (LSP).

LSP is also supported in part by the Department of Veterans Affairs (VA).

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Medicine, General & Internal
  • General & Internal Medicine
  • GLUCOSE-TOLERANCE
  • HEART HEALTH
  • RESTRICTION
  • WOMEN
  • MEN
  • ASSOCIATION
  • COMPLAINTS
  • REVERSES
  • COHORT
  • TIME
  • Sleep duration
  • Diabetes
  • Glucose tolerance test
  • Forced choice questions

Habitual and Recent Sleep Durations: Graded and Interactive Risk for Impaired Glycemic Control in a Biracial Population

Tools:

Journal Title:

American Journal of Medicine

Volume:

Volume 130, Number 5

Publisher:

, Pages 564-571

Type of Work:

Article | Post-print: After Peer Review

Abstract:

Background We examined how habitual sleep duration interacts with recent sleep (2 nights) to predict morning oral glucose tolerance test results. We hypothesized that short habitual and recent sleep durations would be additive for poor glucose control. Methods A biracial population of adults (n = 1559) without known diabetes and recruited from the workforce of 2 urban universities was assessed for glycated hemoglobin and underwent oral glucose tolerance testing. We used plasma 2-hour postloading (75 g) measurements. Participants answered sleep questions using 30-minute forced-choice formats. We employed multivariable logistic regression to derive odds ratios. Results Shorter habitual sleep duration was associated with greater odds ratios of glycated hemoglobin ≥6.0% increasing by 30-minute intervals beginning at < 7.0 hours and were more pronounced as durations shortened. Among participants with glycated hemoglobin < 6.0% and < 7.0 hours of habitual sleep (n = 636), abnormal glucose tolerance (2-hour oral glucose tolerance test ≥140 mg/dL) was significantly associated with a total sleep duration of ≤11 hours the 2 nights preceding oral glucose tolerance testing, but was not associated with longer sleep durations. Results were independent of age, sex, race, body mass index, smoking, history of cardiovascular disease, or use of antihypertensive or cholesterol-lowering medication. Additional analyses implied that longer-than-usual recent sleep durations were protective for abnormal oral glucose tolerance testing. Discussion Short habitual and recent sleep durations interact in predicting abnormal glucose on oral glucose tolerance testing. Self-reported data are sufficiently sensitive to reflect 30-minute differences in sleep between individuals. Future studies examining other aspects of sleep, such as perceived sleep quality and objectively measured sleep duration and architecture, would be necessary to confirm these findings. Conclusions Short sleep duration for 2 nights prior to morning oral glucose tolerance testing may elevate glucose levels, this effect being detected among individuals habitually obtaining < 7 hours sleep and obtaining ≤11 hours of sleep for 2 nights preceding testing.

Copyright information:

© 2017 Elsevier Inc. All rights reserved.

This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Creative Commons License

Export to EndNote